Why insider trading matters?
If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2021-05-07 | Trizzino John | EVP, CCO, CBO & Interim CFO | Sell | 3,212 | $184.94 | $594,030 | Yes |
| 2021-04-30 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 2,895 | $239.83 | $694,317 | Yes |
| 2021-04-19 | Glenn Gregory M | President, R&D | Sell | 8,129 | $206.11 | $1,675,439 | Yes |
| 2021-04-07 | Trizzino John | EVP, Chief Commercial Officer | Sell | 3,212 | $189.38 | $608,296 | Yes |
| 2021-03-26 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 2,894 | $186.80 | $540,609 | Yes |
| 2021-03-25 | YOUNG JAMES F | Director | Sell | 10,000 | $228.22 | $2,282,231 | Yes |
| 2021-03-19 | MCMANUS MICHAEL A JR | Director | Sell | 4,000 | $220.78 | $883,110 | No |
| 2021-03-15 | EVANS GARY C | Director | Sell | 24,500 | $211.21 | $5,174,536 | Yes |
| 2021-03-17 | Glenn Gregory M | President, R&D | Sell | 8,135 | $204.63 | $1,664,704 | Yes |
| 2021-03-09 | Trizzino John | EVP, Chief Commercial Officer | Sell | 3,211 | $163.74 | $525,761 | Yes |
| 2021-02-26 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 2,895 | $225.48 | $652,759 | Yes |
| 2021-02-18 | Glenn Gregory M | President, R&D | Sell | 2,434 | $269.57 | $656,134 | No |
| 2021-02-16 | Glenn Gregory M | President, R&D | Sell | 5,712 | $282.71 | $1,614,812 | Yes |
| 2021-02-09 | Trizzino John | EVP, Chief Commercial Officer | Sell | 3,216 | $292.51 | $940,719 | Yes |
| 2021-02-01 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 15,022 | $241.50 | $3,627,789 | Yes |
| 2021-01-25 | Trizzino John | EVP, Chief Commercial Officer | Sell | 73 | $128.60 | $9,388 | No |
| 2021-01-07 | Trizzino John | EVP, CMO and CBO | Sell | 17,913 | $112.34 | $2,012,353 | Yes |
| 2020-12-31 | YOUNG JAMES F | Director | Sell | 11,000 | $113.09 | $1,244,014 | Yes |
| 2020-11-16 | Erck Stanley C | President and CEO | Sell | 52,316 | $90.65 | $4,742,667 | Yes |
| 2020-09-30 | Trizzino John | EVP, CBO and CFO | Sell | 2,250 | $110.22 | $248,002 | No |
| 2020-10-01 | Erck Stanley C | President and CEO | Sell | 12,233 | $110.23 | $1,348,418 | No |
| 2020-09-29 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 42,779 | $109.04 | $4,664,546 | Yes |
| 2020-09-29 | Glenn Gregory M | President, R&D | Sell | 44,949 | $108.84 | $4,892,300 | Yes |
| 2020-09-29 | Trizzino John | EVP, CBO and CFO | Sell | 43,321 | $109.03 | $4,723,086 | Yes |
| 2020-09-29 | Erck Stanley C | President and CEO | Sell | 29,112 | $109.95 | $3,200,722 | Yes |
| 2020-08-18 | Trizzino John | EVP, CBO and CFO | Sell | 42,788 | $148.78 | $6,366,182 | Yes |
| 2020-08-18 | MCMANUS MICHAEL A JR | Director | Sell | 8,000 | $146.00 | $1,168,000 | Yes |
| 2020-08-18 | Herrmann John A III | EVP, Chief Legal Officer | Sell | 46,242 | $144.33 | $6,673,982 | Yes |
| 2020-08-18 | Glenn Gregory M | President, R&D | Sell | 55,921 | $145.20 | $8,119,860 | Yes |
| 2020-08-18 | EVANS GARY C | Director | Sell | 10,500 | $150.44 | $1,579,620 | Yes |
Insider Smart
Insider Smart